<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Apremilast: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Apremilast: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Apremilast: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="94784" href="/d/html/94784.html" rel="external">see "Apremilast: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24162120"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Otezla</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871738"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Apremilast;</li>
<li>AURO-Apremilast;</li>
<li>GLN-Apremilast;</li>
<li>JAMP-Apremilast;</li>
<li>MINT-Apremilast;</li>
<li>Otezla;</li>
<li>PMS-Apremilast;</li>
<li>SANDOZ Apremilast</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F24140931"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphodiesterase-4 Enzyme Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F24181382"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="436ae79e-48fb-4e34-a352-30ed4465e72c">Behçet disease, psoriasis, or psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Behçet disease, psoriasis, or psoriatic arthritis: </b>Oral: Initial: 10 mg in the morning on day 1. Titrate upward by additional 10 mg per day on days 2 to 5 as follows: Day 2: 10 mg twice daily; Day 3: 10 mg in the morning and 20 mg in the evening; Day 4: 20 mg twice daily; Day 5: 20 mg in the morning and 30 mg in the evening. Maintenance dose: 30 mg twice daily starting on day 6.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990462"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Initial: 10 mg once daily in the morning on days 1 to 3; titrate using morning doses only (skip evening doses) to 20 mg once daily on days 4 and 5. Maintenance dose: 30 mg once daily in the morning starting on day 6.</p></div>
<div class="block doha drugH1Div" id="F50987705"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F24181383"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58703336"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects such as <b>diarrhea</b>, <b>nausea</b>, and <b>vomiting</b>, including severe cases, have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493'])">Ref</a></span>). GI effects typically resolve with continued treatment within ~4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077258','lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077258','lexi-content-ref-32710493'])">Ref</a></span>); however, dose reduction or discontinuation may be necessary for severe symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action; phosphodiesterase 4 (PDE4) inhibition and increased cyclic adenosine monophosphate levels lead to activation of membrane chloride channels and subsequent fluid secretion into the gut, causing diarrhea. PDE4 inhibition and increased cyclic adenosine monophosphate levels may also contribute to both central and peripheral mechanisms that lead to nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32710493'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; usually within the first 2 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (for complications from severe GI effects):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients ≥65 years</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients taking medications that may lead to volume depletion or hypotension</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neuropsychiatric effects (eg, <b>anxiety</b>, <b>depression,</b> mood changes, <b>suicidal ideation, suicidal tendencies</b>) have been reported rarely with apremilast (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493','lexi-content-ref-31981426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493','lexi-content-ref-31981426'])">Ref</a></span>). In one cohort study of patients with psoriasis, users of apremilast had similar rates of anxiety plus depression as users of other noncorticosteroid systemic psoriasis treatments; however, the rate of anxiety was higher (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31981426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31981426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; occurred within 2 years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077258','lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077258','lexi-content-ref-32710493'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• History of bipolar disorder, depression, and/or emotional or physical abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077258','lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077258','lexi-content-ref-32710493'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight loss</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Over 52 weeks or longer, the mean <b>weight loss</b> with apremilast in the clinical trial population was ~1% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32710493'])">Ref</a></span>). Over 156 weeks, the mean weight loss was 1.5% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416342'])">Ref</a></span>). Weight loss &gt;5% has been reported in 12% to 14% of patients in the first 24 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32710493'])">Ref</a></span>). Over follow-up at 3 to 5 years, 20% to 22% of patients lost &gt;5% body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28416342','lexi-content-ref-31077258','lexi-content-ref-32710493'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to pharmacologic action; phosphodiesterase 4 inhibition increases secretion of glucagon-like-peptide-1, which stimulates insulin secretion and inhibits glucagon secretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32710493'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; within 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32710493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32710493'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F24161119"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (&gt;5% of body weight: 5%; 5% to 10% of body weight: 10% to 12%; ≥10% of body weight: 2%)<span class="lexi-table-link-container"> (<a aria-label="Weight Loss table link" class="lexi-table-link" data-table-id="lexi-content-weight-loss" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-loss')">table 1</a>)</span><span class="table-link" style="display:none;">Weight Loss</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Loss" frame="border" id="lexi-content-weight-loss" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Weight Loss</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Behçet disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;5% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">784</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">382</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5% to 10% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">784</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">382</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥10% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">497</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5% to 10% of body weight</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (8% to 41%; severe diarrhea: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 2</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (7% to 22%; severe nausea: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 3</a>)</span><span class="table-link" style="display:none;">Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">41%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Behçet disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to week 12</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">920</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to day 112</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">497</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 1 to day 5</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">490</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 6 to day 112</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Behçet disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to week 12</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">920</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to day 112</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">490</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 6 to day 112</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">497</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 1 to day 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (5% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (4% to 12%; viral upper respiratory tract infection: 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Folliculitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4%; upper abdominal pain: ≤9%), decreased appetite (3%), dyspepsia (3%), frequent bowel movements (2%), tooth abscess (1%), vomiting (0.8% to 9%; severe vomiting: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 4</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Behçet disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to week 12</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">920</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Up to day 112</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">493</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">490</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 6 to day 112</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">497</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 1 to day 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depressed mood (≤1%), depression (≤1%; severe depression: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Depression table link" class="lexi-table-link" data-table-id="lexi-content-depression" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-depression')">table 5</a>)</span><span class="table-link" style="display:none;">Depression</span>, fatigue (3%), insomnia (2%), migraine (2%), tension headache (8%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Depression" frame="border" id="lexi-content-depression" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Depression</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Behçet disease</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">104</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as depression or depressed mood</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">920</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe depression: 0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,308</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">998</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as depression or depressed mood</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe depression: 0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,441</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as depression or depressed mood</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (6%), back pain (2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1%), nasopharyngitis (3%), sinus headache (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exacerbation of psoriasis (rebound following discontinuation)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Suicidal ideation<span class="lexi-table-link-container"> (<a aria-label="Suicidal Ideation table link" class="lexi-table-link" data-table-id="lexi-content-suicidal-ideation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-suicidal-ideation')">table 6</a>)</span><span class="table-link" style="display:none;">Suicidal Ideation</span>, suicidal tendencies<span class="lexi-table-link-container"> (<a aria-label="Suicidal Tendencies table link" class="lexi-table-link" data-table-id="lexi-content-suicidal-tendencies" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-suicidal-tendencies')">table 7</a>)</span><span class="table-link" style="display:none;">Suicidal Tendencies</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Suicidal Ideation" frame="border" id="lexi-content-suicidal-ideation" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Suicidal Ideation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,441</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as suicidal ideation and behavior</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Suicidal Tendencies" frame="border" id="lexi-content-suicidal-tendencies" rules="all">
<caption style="text-align:center;">
<b>Apremilast: Adverse Reaction: Suicidal Tendencies</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Apremilast)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe plaque psoriasis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,308</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">506</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Psoriatic arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,441</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">495</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as suicidal ideation and behavior</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroesophageal reflux disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (Vasilakis-Scaramozza 2020)</p></div>
<div class="block coi drugH1Div" id="F24140934"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to apremilast or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F24181364"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in renal impairment. Systemic exposure is increased in patients with severe renal impairment (CrCl &lt;30 mL/minute); dosage reduction is recommended.</p></div>
<div class="block foc drugH1Div" id="F24162121"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otezla: 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otezla: 10 &amp; 20 &amp; 30 mg (55 ea)</p></div>
<div class="block geq drugH1Div" id="F24162119"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F24744550"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Otezla Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 &amp; 20 &amp; 30 mg (per each): $105.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Otezla Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $96.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871739"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otezla: 30 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otezla: 10 &amp; 20 &amp; 30 mg (27 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 &amp; 20 &amp; 30 mg (27 ea)</p></div>
<div class="block adm drugH1Div" id="F24181386"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer  without regard to food. Do not crush, chew, or split tablets. </p></div>
<div class="block use drugH1Div" id="F24140933"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Behçet disease:</b> Treatment of oral ulcers associated with Behçet disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis:</b> Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis:</b> Treatment of patients with active psoriatic arthritis.</p></div>
<div class="block cyt drugH1Div" id="F24180693"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F24180690"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Apremilast may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding apremilast for 1 to 2 weeks after vaccine administration as permitted by the underlying disease. These guidelines consider apremilast to be an immunomodulatory or immunosuppressive medication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Apremilast.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Apremilast.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Apremilast may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53490754"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to apremilast may cause an increase in pregnancy loss. According to the manufacturer, pregnancy planning and prevention should be considered for patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for use of apremilast to treat rheumatic and musculoskeletal diseases in patients planning to become pregnant or patients who are planning to father a child are not available due to lack of data (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F24181361"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to apremilast may cause an increase in pregnancy loss.</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for use of apremilast in pregnant patients with rheumatic and musculoskeletal diseases are not available due to lack of data. Placental transfer may be expected based on molecular weight (ACR [Sammaritano 2020]).</p></div>
<div class="block brc drugH1Div" id="F24181363"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if apremilast is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Recommendations for use of apremilast in breastfeeding patients with rheumatic and musculoskeletal diseases are not available due to lack of data. Transfer into breast milk may be expected based on molecular weight (ACR [Sammaritano 2020]).</p></div>
<div class="block mop drugH1Div" id="F24181388"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor weight regularly during therapy; renal function; signs or symptoms of mood changes, depression, or suicidal thoughts; diarrhea or vomiting, especially patients more susceptible to complications of diarrhea (eg, older patients, patients taking medications that may lead to volume depletion or hypotension).</p></div>
<div class="block pha drugH1Div" id="F24181367"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Apremilast inhibits phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP) which results in increased intracellular cAMP levels and regulation of numerous inflammatory mediators (eg, decreased expression of nitric oxide synthase, TNF-α, and interleukin [IL]-23, as well as increased IL-10) (Schafer, 2012). </p></div>
<div class="block phk drugH1Div" id="F24181369"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 87 L </p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~68%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via CYP3A4: minor pathways include CYP1A2 and CYP2A6</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~73%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~6 to 9 hours </p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (58%; 3% unchanged drug); feces (39%; 7% unchanged drug) </p></div>
<div class="block phksp drugH1Div" id="F51220443"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The AUC and C<sub>max</sub> of apremilast increased by ~88% and 42%, respectively, in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The apremilast exposure in elderly subjects (65 to 85 years of age) was about 13% higher in AUC and about 6% higher in C<sub>max</sub> than in younger subjects (18 to 55 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: The extent of exposure in females was about 31% higher and C<sub>max</sub> was about 8% higher than that in male subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F28753594"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aprima | Arsenor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Otezla</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Otezla</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Apremax</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Otezla</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aprezo</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Otezla</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Otezla | Otezla Titration Pack</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Otezla</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Otezla</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28416342">
<a name="28416342"></a>Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). <i>J Am Acad Dermatol</i>. 2017;77(2):310-317.e1. doi:10.1016/j.jaad.2017.01.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apremilast-drug-information/abstract-text/28416342/pubmed" id="28416342" target="_blank">28416342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077258">
<a name="31077258"></a>Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. <i>Arthritis Res Ther</i>. 2019;21(1):118. doi:10.1186/s13075-019-1901-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apremilast-drug-information/abstract-text/31077258/pubmed" id="31077258" target="_blank">31077258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32710493">
<a name="32710493"></a>Mease PJ, Gladman DD, Gomez-Reino JJ, et al. Long-term safety and tolerability of apremilast versus placebo in psoriatic arthritis: A pooled safety analysis of three phase III, randomized, controlled trials. <i>ACR Open Rheumatol</i>. 2020;2(8):459-470. doi:10.1002/acr2.11156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apremilast-drug-information/abstract-text/32710493/pubmed" id="32710493" target="_blank">32710493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Otezla.1">
<a name="Otezla.1"></a>Otezla (apremilast) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Otezla.2">
<a name="Otezla.2"></a>Otezla (apremilast) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apremilast-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22257911">
<a name="22257911"></a>Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. <i>Biochem Pharmacol</i>. 2012;83(12):1583-1590. doi:10.1016/j.bcp.2012.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apremilast-drug-information/abstract-text/22257911/pubmed" id="22257911" target="_blank">22257911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31981426">
<a name="31981426"></a>Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: A cohort study in the United States MarketScan database. <i>J Eur Acad Dermatol Venereol</i>. 2020;34(8):1755-1763. doi:10.1111/jdv.16231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apremilast-drug-information/abstract-text/31981426/pubmed" id="31981426" target="_blank">31981426</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 94524 Version 170.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
